| Sunosi (solriamfetol) / Axsome Therap, Pharmanovia |
NCT04622293: A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
|
|
| Active, not recruiting | 4 | 44 | US | Solriamfetol Oral Tablet [Sunosi], Sunosi, Placebo | Rochester Center for Behavioral Medicine | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | 03/24 | 05/24 | | |
NCT04788953: Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder |
|
|
| Recruiting | 4 | 110 | US | Solriamfetol Oral Tablet, Sunosi, Placebo | Charles A. Czeisler, PhD, MD, Axsome Therapeutics, Inc. | Excessive Sleepiness, Shift-work Disorder | 04/24 | 11/24 | | |
| Recruiting | 4 | 64 | US | Solriamfetol, Sunosi, Placebo | Lindner Center of HOPE, Jazz Pharmaceuticals | Binge Eating Disorder | 08/24 | 12/24 | | |
NCT05838430: Solriamfetol and CBT-I in Patients With Insomnia Disorder |
|
|
| Recruiting | 4 | 60 | US | Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo | University of Pennsylvania, Axsome Therapeutics, Inc. | Insomnia | 07/25 | 12/25 | | |
| Recruiting | 3 | 300 | US | Solriamfetol 300 mg, Placebo | Axsome Therapeutics, Inc. | Major Depressive Disorder | 12/25 | 12/25 | | |
ENGAGE, NCT06413433: Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol |
|
|
| Recruiting | 3 | 450 | US | Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo | Axsome Therapeutics, Inc. | Binge-Eating Disorder | 12/25 | 12/25 | | |
SOL-SWD-301, NCT06568367: Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) |
|
|
| Recruiting | 3 | 520 | US | Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo | Axsome Therapeutics, Inc. | Excessive Sleepiness, Shift-work Disorder | 12/26 | 12/26 | | |
NCT06103825: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA) |
|
|
| Recruiting | 3 | 204 | RoW | Solriamfetol, Placebo | Ignis Therapeutics (Suzhou) Limited | Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea | 09/24 | 10/24 | | |
NCT05972044: A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) |
|
|
| Recruiting | 3 | 450 | US | Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo | Axsome Therapeutics, Inc. | ADHD | 12/24 | 12/24 | | |
NCT04839562: A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults |
|
|
| Completed | 2/3 | 66 | US | Solriamfetol 75 MG, Sunosi 75 mg, Solriamfetol 150 MG, Sunosi 150 mg, Placebo | Massachusetts General Hospital | Attention Deficit Hyperactivity Disorder | 01/23 | 01/23 | | |
| Recruiting | 2 | 46 | US | Solriamfetol, Sunosi, Placebo | Johns Hopkins University, National Multiple Sclerosis Society, Axsome Therapeutics, Inc. | Multiple Sclerosis, Multiple Sclerosis Fatigue | 12/26 | 03/27 | | |
| Recruiting | 2 | 1074 | US | Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo | Duke University | Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance | 07/25 | 07/25 | | |
NCT06404099: RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) |
|
|
| Recruiting | 2 | 474 | US | Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo | Duke University | Long COVID, Long COVID-19, Hypersomnia | 11/25 | 11/25 | | |
SOLR-IH, NCT06590662: Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia. |
|
|
| Not yet recruiting | 2 | 60 | Europe | Solriamfetol, Placebo | University Hospital, Montpellier | Idiopathic Hypersomnia | 11/26 | 06/27 | | |
| Recruiting | N/A | 1731 | US | Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment | Axsome Therapeutics, Inc. | Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring | 09/29 | 09/29 | | |
| Recruiting | N/A | 1329 | US | Pitolisant, Wakix, Comparator Products, Modafinil/armodafinil, Sodium oxybate, Oxybate mixed salts, Solriamfetol, Methylphenidate, Amphetamines | Harmony Biosciences, LLC | Pregnancy Related, Narcolepsy | 06/30 | 06/30 | | |
| Auvelity (bupropion/dextromethorphan) / Axsome Therap |
NCT06223880: A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms |
|
|
| Recruiting | 4 | 350 | US | AXS-05, Bupropion | Axsome Therapeutics, Inc. | Major Depressive Disorder | 03/26 | 03/26 | | |
AXS-05-AD-303, NCT04947553: A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation |
|
|
| Enrolling by invitation | 3 | 300 | Canada, US | AXS-05 (dextromethorphan-bupropion), Placebo | Axsome Therapeutics, Inc. | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 12/24 | 12/24 | | |
ADVANCE-2, NCT05557409: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation |
|
|
| Recruiting | 3 | 350 | US | AXS-05, Placebo | Axsome Therapeutics, Inc. | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation | 06/25 | 06/25 | | |
| Not yet recruiting | 2 | 60 | US | AXS-05, Bupropion/dextromethorphan, Bupropion SR, Wellbutrin SR, Zyban SR | James Davis, Axsome Therapeutics, Inc. | Smoking Cessation, Smoking, Cigarette, Nicotine Dependence | 12/18 | 01/19 | | |
TARGET, NCT04971291: An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients |
|
|
| Enrolling by invitation | 2 | 312 | US | AXS-05, Bupropion SR | Axsome Therapeutics, Inc. | Major Depressive Disorder, Treatment Resistant Depression | 07/21 | 07/21 | | |
NCT05976646: Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion |
|
|
| Recruiting | 1/2 | 18 | US | Placebo, Auvelity | Virginia Commonwealth University, National Institute on Drug Abuse (NIDA) | Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder | 01/25 | 01/25 | | |
| zoledronate (AXS-02) / Axsome Therap |
2015-001527-22: CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I) |
|
|
| Not yet recruiting | 3 | 190 | Europe | Disodium Zoledronate Tetrahydrate, AXS-02, Tablet | Axsome Therapeutics, Inc., Axsome Therapeutics, Inc. | Complex regional pain syndrome (CRPS-I)., Severe pain in a limb accompanied by autonomic, sensory, motor and trophic changes, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
2015-000751-25: Zoledronic acid, an osteoporosis drug, in chronic low back pain with specific findings on magnetic resonance imaging: a randomized controlled trial Zoledronihappo, osteoporoosilääke, kroonisessa alaselkäkivussa jossa on spesifisiä löydöksiä magneettikuvauksessa: satunnaistettu kontrolloitu tutkimus |
|
|
| Ongoing | 2 | 250 | Europe | Disodium Zoledronate Tetrahydrate, AXS-02, Tablet | Jaro Karppinen, Axsome Therapeutics Inc. | Chronic low back pain Krooninen alaselkäkipu, Longlasting pain in the lower back Pitkäkestoinen alaselkäkipu, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| reboxetine (AXS-12) / Axsome Therap |
SYMPHONY, NCT05059223: A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy |
|
|
| Completed | 3 | 90 | Canada, US | AXS-12 (reboxetine), Placebo | Axsome Therapeutics, Inc. | Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | 03/24 | 03/24 | | |
NCT05113745: A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy |
|
|
| Enrolling by invitation | 3 | 90 | Canada, US | AXS-12 (reboxetine), Placebo | Axsome Therapeutics, Inc. | Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | 12/24 | 12/24 | | |
| meloxicam/rizatriptan (AXS-07) / Axsome Therap |
EMERGE, NCT05550207: Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor |
|
|
| Recruiting | 3 | 100 | US | AXS-07 (meloxicam-rizatriptan) | Axsome Therapeutics, Inc. | Migraine | 12/24 | 12/24 | | |
| esreboxetine (AXS-14) / Axsome Therap, Pfizer |
| No trials found |
